CORRECTION

Open Access

Correction: Evaluation of the anticancer potential of CD44 targeted vincristine nanoformulation in prostate cancer xenograft model: a multi-dynamic approach for advanced pharmacokinetic evaluation

Faiza Naseer^{1,2*}, Kousain Kousar¹, Maisa S. Abduh³, Sadia Anjum⁴ and Tahir Ahmad^{1*}

The original article can be found online at https://doi.org/10.1186/s12645-023-00218-2.

*Correspondence: faiza.naseer@ymail.com; tahir@asab.nust.edu.pk

¹ Industrial Biotechnology, Atta-ur-Rahman School of Applied Biosciences, National University of Sciences and Technology, Islamabad, Pakistan 2 Schie Collogo of Decemponitie

² Shifa College of Pharmaceutical Sciences, Shifa Tameer e Millat University, Islamabad, Pakistan ³ Immune Responses in Different Diseases Research Group, Department of Medical Laboratory Sciences, Faculty of Applied Medical Sciences, King Abdul-Aziz University, Jeddah 21589, Saudi Arabia ⁴ Department of Biology, University of Hail, Hail, Saudi Arabia

Correction: Cancer Nanotechnology (2023) 14:65 https://doi.org/10.1186/s12645-023-00218-2

Following publication of the original article (Naseer et al. 2023), the below Acknowledgement was missing.

Acknowledgement

We gratefully acknowledge the technical and financial support of the Deanship of Scientific Research (DSR) provided at King Abdulaziz University, Jeddah, Saudi Arabia under Grant No. (FP-225-43).

The original article (Naseer et al. 2023) has been corrected.

Published online: 06 July 2023

Reference

Naseer F, Kousar K, Abduh MS, Anjum S, Ahmad T (2023) Evaluation of the anticancer potential of CD44 targeted vincristine nanoformulation in prostate cancer xenograft model: a multi-dynamic approach for advanced pharmacokinetic evaluation. Cancer Nano 14:65. https://doi.org/10.1186/s12645-023-00218-2

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



© The Author(s) 2023. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http:// creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/public cdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.